Archive · 24 Jul 2026
Trump's Tariffs on Generic Drugs Spark Industry Concerns
President Trump has proposed new tariffs on generic drugs imported into the US.
The plan is to have no tariffs for two years, then increase to 100% in the third year, and 200% in the fourth year.
The goal is to encourage drug companies to start making more generic drugs in the US.
However, experts from the Indian pharmaceutical industry, which supplies many of these drugs, say the plan is not realistic.
They argue that the timeline is too short and the tariffs are too high for companies to adjust.
They also worry that the tariffs could disrupt the supply of affordable medicines to the US.
The Indian industry plans to continue working with the US government to find a better solution.
US President Donald Trump proposed tariffs on generic drugs to incentivize domestic production.
Tariffs will be 0% until August 1, 2028, then increase to 100% and 200% in subsequent years.
Indian pharmaceutical industry experts argue the timeline is too short and margins too thin to absorb the tariffs.
India supplies over one-third of the US's generic drugs and has over 40 manufacturing facilities in the US.
The Indian Pharmaceutical Alliance will engage with the US Administration to build a stronger partnership.
- Who
- US President Donald Trump and the Indian pharmaceutical industry
- What
- Proposed tariffs on generic drugs imported into the US
- When
- Announced on Wednesday (local time), with tariffs scheduled to increase from August 2028
- Where
- United States and India
- Why
- To bring generic pharmaceutical production back to the United States and reduce dependency on foreign supplies
US Government Perspective
Indian Pharmaceutical Industry Perspective
Feasibility of Tariff Implementation
US Government Perspective
The US government believes the tariffs will incentivize generic drug production within the US, bringing jobs and manufacturing back to the country.
Indian Pharmaceutical Industry Perspective
The Indian pharmaceutical industry argues that the timeline is too short and the tariffs are too high to be feasible, given the current thin operating margins.
Impact on Supply Chains
US Government Perspective
The US aims to reduce dependency on foreign pharmaceutical supplies by encouraging domestic production.
Indian Pharmaceutical Industry Perspective
Indian companies warn that the tariffs could disrupt supply chains and force them to withdraw from the US market, affecting affordable drug supplies.
- Proposed Tariff Schedule
- 0% until August 1, 2028; 100% from August 2028; 200% from August 2029
- Current Indian Pharmaceutical Exports to the US
- Over one-third of India's pharmaceutical exports
- Indian Pharmaceutical Facilities in the US
- Over 40 facilities
- Indian Pharmaceutical Industry Margin
- Very low, making it difficult to absorb tariffs
- US Presidential Election Timeline
- January 2029
